Source:http://linkedlifedata.com/resource/pubmed/id/17021609
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
2006-11-2
|
| pubmed:abstractText |
Intravenous vitamin D is standard therapy for secondary hyperparathyroidism in hemodialysis (HD) patients. In for-profit dialysis clinics, mortality was higher for patients on calcitriol compared to paricalcitol. Doxercalciferol, a second vitamin D2 analog, is currently available. We assessed mortality associated with each vitamin D analog and with lack of vitamin D therapy in patients who began HD at Dialysis Clinic Inc. (DCI), a not-for-profit dialysis provider. During the 1999-2004 study period we studied 7731 patients (calcitriol: n=3212; paricalcitol: n=2087; doxercalciferol: n=2432). Median follow-up was 37 weeks. Mortality rates (deaths/100 patient-years) were identical in patients on doxercalciferol (15.4, 95% confidence interval (13.6-17.1)) and paricalcitol (15.3 (13.6-16.9)) and higher in patients on calcitriol (19.6 (18.2-21.1)) (P<0.0001). In all models mortality was similar for paricalcitol versus doxercalciferol (hazard ratios=1.0). In unadjusted models, mortality was lower in patients on doxercalciferol (0.80 (0.66, 0.96)) and paricalcitol (0.79 (0.68, 0.92)) versus calcitriol (P<0.05). In adjusted models, this difference was not statistically significant. In all models mortality was higher for patients who did not receive vitamin D versus those who did (1.2 (1.1-1.3)). Mortality in doxercalciferol- and paricalcitol-treated patients was virtually identical. Differences in survival between vitamin D2 and D3 may be smaller than previously reported.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/1 alpha-hydroxyergocalciferol,
http://linkedlifedata.com/resource/pubmed/chemical/Bone Density Conservation Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Calcitriol,
http://linkedlifedata.com/resource/pubmed/chemical/Calcium,
http://linkedlifedata.com/resource/pubmed/chemical/Ergocalciferols,
http://linkedlifedata.com/resource/pubmed/chemical/Parathyroid Hormone,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphorus,
http://linkedlifedata.com/resource/pubmed/chemical/Vitamin D,
http://linkedlifedata.com/resource/pubmed/chemical/paricalcitol
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0085-2538
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
70
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1858-65
|
| pubmed:dateRevised |
2007-12-19
|
| pubmed:meshHeading |
pubmed-meshheading:17021609-Adult,
pubmed-meshheading:17021609-Aged,
pubmed-meshheading:17021609-Aged, 80 and over,
pubmed-meshheading:17021609-Bone Density Conservation Agents,
pubmed-meshheading:17021609-Bone Diseases, Metabolic,
pubmed-meshheading:17021609-Calcitriol,
pubmed-meshheading:17021609-Calcium,
pubmed-meshheading:17021609-Ergocalciferols,
pubmed-meshheading:17021609-Female,
pubmed-meshheading:17021609-Humans,
pubmed-meshheading:17021609-Hyperparathyroidism, Secondary,
pubmed-meshheading:17021609-Kidney Failure, Chronic,
pubmed-meshheading:17021609-Male,
pubmed-meshheading:17021609-Middle Aged,
pubmed-meshheading:17021609-Parathyroid Hormone,
pubmed-meshheading:17021609-Phosphorus,
pubmed-meshheading:17021609-Renal Dialysis,
pubmed-meshheading:17021609-Retrospective Studies,
pubmed-meshheading:17021609-Risk Factors,
pubmed-meshheading:17021609-Survival Analysis,
pubmed-meshheading:17021609-Vitamin D
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Mortality risk among hemodialysis patients receiving different vitamin D analogs.
|
| pubmed:affiliation |
Dialysis Clinic Inc., Albuquerque, New Mexico, USA.
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|